146 related articles for article (PubMed ID: 2076745)
1. Pharmacokinetics and metabolism of iodo-doxorubicin and doxorubicin in humans.
Mross K; Mayer U; Hamm K; Burk K; Hossfeld DK
Eur J Clin Pharmacol; 1990; 39(5):507-13. PubMed ID: 2076745
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.
Mross K; Maessen P; van der Vijgh WJ; Gall H; Boven E; Pinedo HM
J Clin Oncol; 1988 Mar; 6(3):517-26. PubMed ID: 3162516
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and metabolism of 4'-iodo-4'-deoxy-doxorubicin in humans.
Robert J; Armand JP; Huet S; Klink-Alakl M; Recondo G; Hurteloup P
J Clin Oncol; 1992 Jul; 10(7):1183-90. PubMed ID: 1607922
[TBL] [Abstract][Full Text] [Related]
4. Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial.
de Jong J; Geijssen GJ; Munniksma CN; Vermorken JB; van der Vijgh WJ
J Clin Oncol; 1992 Dec; 10(12):1897-906. PubMed ID: 1453205
[TBL] [Abstract][Full Text] [Related]
5. Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study.
Camaggi CM; Comparsi R; Strocchi E; Testoni F; Angelelli B; Pannuti F
Cancer Chemother Pharmacol; 1988; 21(3):221-8. PubMed ID: 3162849
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic and pharmacokinetic aspects of iodo-doxorubicin.
Mross K; Mayer U; Zeller W; Becker K; Hossfeld DK
Oncol Res; 1992; 4(6):227-31. PubMed ID: 1421615
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of doxorubicin and its active metabolite in patients with normal renal function and in patients on hemodialysis.
Yoshida H; Goto M; Honda A; Nabeshima T; Kumazawa T; Inagaki J; Yamanaka N; Ota K
Cancer Chemother Pharmacol; 1994; 33(6):450-4. PubMed ID: 8137454
[TBL] [Abstract][Full Text] [Related]
8. [Iodo-doxorubicin, a new anthracycline derivative. Current state of progress].
Mross KB; Langenbuch T; Burk K; Hossfeld DK
Onkologie; 1990 Oct; 13(5):346-51. PubMed ID: 2082229
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin pharmacokinetics in the rabbit.
Maniez-Devos DM; Baurain R; Trouet A; Lesne M
J Pharmacol; 1985; 16(2):159-69. PubMed ID: 4058012
[TBL] [Abstract][Full Text] [Related]
10. Pharmacology and clinical toxicity of 4'-iodo-4'-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials.
Gianni L; Viganò L; Surbone A; Ballinari D; Casali P; Tarella C; Collins JM; Bonadonna G
J Natl Cancer Inst; 1990 Mar; 82(6):469-77. PubMed ID: 2313718
[TBL] [Abstract][Full Text] [Related]
11. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin.
Erlichman C; Moore M; Thiessen JJ; Kerr IG; Walker S; Goodman P; Bjarnason G; DeAngelis C; Bunting P
Cancer Res; 1993 Oct; 53(20):4837-42. PubMed ID: 8402670
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients].
Wihlm J; Limacher JM; Levêque D; Duclos B; Dufour P; Bergerat JP; Methlin G
Bull Cancer; 1997 Jun; 84(6):603-8. PubMed ID: 9295863
[TBL] [Abstract][Full Text] [Related]
13. Improved high-performance liquid chromatography assay of doxorubicin: detection of circulating aglycones in human plasma and comparison with thin-layer chromatography.
Brenner DE; Galloway S; Cooper J; Noone R; Hande KR
Cancer Chemother Pharmacol; 1985; 14(2):139-45. PubMed ID: 3971478
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer.
Swenson CE; Bolcsak LE; Batist G; Guthrie TH; Tkaczuk KH; Boxenbaum H; Welles L; Chow SC; Bhamra R; Chaikin P
Anticancer Drugs; 2003 Mar; 14(3):239-46. PubMed ID: 12634619
[TBL] [Abstract][Full Text] [Related]
15. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: Estimation of doxorubicin hepatic extraction ratio.
Pippa LF; Oliveira ML; Rocha A; de Andrade JM; Lanchote VL
J Pharm Biomed Anal; 2020 Jun; 185():113231. PubMed ID: 32163849
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of anthracyclines.
Eksborg S
Acta Oncol; 1989; 28(6):873-6. PubMed ID: 2611038
[TBL] [Abstract][Full Text] [Related]
17. Effect of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbit.
Cusack BJ; Tesnohlidek DA; Loseke VL; Vestal RE; Brenner DE; Olson RD
Cancer Chemother Pharmacol; 1988; 22(4):294-8. PubMed ID: 3168142
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit.
Cusack BJ; Young SP; Driskell J; Olson RD
Cancer Chemother Pharmacol; 1993; 32(1):53-8. PubMed ID: 8462124
[TBL] [Abstract][Full Text] [Related]
19. Comparative metabolism and pharmacokinetics of doxorubicin and 4'-epidoxorubicin in plasma, heart and tumor of tumor-bearing mice.
van der Vijgh WJ; Maessen PA; Pinedo HM
Cancer Chemother Pharmacol; 1990; 26(1):9-12. PubMed ID: 2322993
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and metabolism of pirarubicin in advanced cancer patients.
Robert J; David M; Huet S; Chauvergne J
Eur J Cancer Clin Oncol; 1988 Aug; 24(8):1289-94. PubMed ID: 3181250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]